Navigation Links
Immune-Boosting Lung Cancer Therapy Shows Promise
Date:4/25/2008

It cut relapse after surgery to same extent as chemo but without side effects

FRIDAY, April 25 (HealthDay News) -- An immune-boosting treatment for lung cancer patients reduces the risk of cancer relapse after surgery to the same extent as chemotherapy but without the risk of unpleasant side effects, says a Phase II study by Belgian researchers.

The study included 182 patients with non-small-cell lung cancer, the most common form of the disease. All the patients had surgery to remove their cancer and were then randomly assigned to receive either a placebo or MAGE-A3 ASCI (antigen-specific cancer immunotherapeutic) injections over 27 months -- five given at three-week intervals, followed by eight given once every three months.

MAGE-A3 is a tumor-specific antigen produced in 35 percent to 50 percent of non-small-cell lung cancer. It's not produced by normal cells.

"The aim is to help the body's immune system to recognize the MAGE-A3 antigen and therefore eliminate the cancer cells that express MAGE-A3. In other words, it is a kind of treatment method that makes the body's immune system specifically attack cancer cells," study author Professor Johan Vansteenkiste, of the University Hospital Gasthuisberg, said in a prepared statement.

After 44 months of follow-up, cancer had recurred in 69 of the 182 patients, including 57 deaths. Patients who received the MAGE-A3 injections were less likely to have any recurrence, went longer without recurrence, and were less likely to die.

The findings were to be presented April 25 at the European Lung Cancer Conference in Geneva.

"Surgical resection is the standard treatment for patients with early stage lung cancer, but after complete resection, about 50 percent will relapse and die from their cancer," Vansteenkiste said. "Postoperative chemotherapy is able to improve cure rates but is sometimes poorly tolerated by patients recovering from thoracic surgery. In addition, not all patients are fit to receive chemotherapy."

This study shows that MAGE-A3 ASCI provides benefits similar to chemotherapy with only minimal side effects, such as mild reactions at the injection site and fever within 24 hours of the injection.

"Therefore, it is suitable for long-term maintenance treatment and, for most patients, including older patients or patients in weak physical condition after surgery, allowing them to live a normal life whilst on cancer treatment," Vansteenkiste said.

A Phase III trial of MAGE-A3 ASCI is now under way.

More information

The U.S. National Cancer Institute has more about lung cancer.



-- Robert Preidt



SOURCE: European Society for Medical Oncology, news release, April 25, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Possible Viral Links to Lung Cancer Risk Uncovered
2. New genetic techniques to combat lung cancer
3. Analysis shows combining sorafenib with carboplatin/paclitaxel adds no benefit in lung cancer
4. Mutation database helps personalized treatment of lung cancer
5. Breast cancer subtypes originate from different biological pathways
6. New lymphoma therapies targets diverse and difficult cancer
7. Cancer researchers receive NIH grant to advance brain tumor therapies from lab to clinical trials
8. $450,000 sweetener in colon cancer battle
9. Support for Patient Navigation Services to Help Cancer Patients
10. Gene Predicts Breast Cancer Prognosis
11. West Coast Bank Supports the Childrens Cancer Association With a $5,000 Commitment
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Immune-Boosting Lung Cancer Therapy  Shows Promise
(Date:6/27/2016)... ... June 27, 2016 , ... ... strategic partnership with Connance, a healthcare industry leader providing predictive analytics to ... technology combine to provide health systems, hospitals and ambulatory surgical centers with ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, ... editors can give their videos a whole new perspective by using the title ... Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to choose ...
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World ... with chronic pain and the benefits of holistic treatments, Serenity Recovery Center ... with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... 2016 The Academy of Managed Care Pharmacy ... that would allow biopharmaceutical companies to more easily share ... formulary and coverage decisions, a move that addresses the ... The recommendations address restrictions in the sharing ... drug label, a prohibition that hinders decision makers from ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
Breaking Medicine Technology: